Roger von Moos et al. (trial SAKK 96/12 / REDUSE): Prevention of symptomatic skeletal events with Denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): a non-inferiority phase III trial. 

Metaxas Ioannis et al. (trial SAKK 17/16): Lurbinectedin monotherapy in patients with progressive malignant pleural mesothelioma. A multicenter, single-arm, phase II Trial.
Huober Jens et al. (trial SAKK 22/10 / unicancer uc-0140/1207): Pernetta – A non comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2 positive metastatic breast cancer. 
Vees Hansjörg et al. (trial SAKK 15/12): Impact of early prophylactic cranial irradiation with hippocampal avoidance on neurocognitive function in patients with limited disease small-cell lung cancer. A multicenter phase II trial.
We wish the authors every success with their presentations and would like to thank everyone involved for their work.